Literature DB >> 24134561

Mizoribine selectively attenuates monocyte chemoattractant protein-1 production in cultured human glomerular mesangial cell: a possible benefit of its use in the treatment of lupus nephritis.

Tomomi Aizawa1, Tadaatsu Imaizumi, Kazushi Tsuruga, Shojiro Watanabe, Yuki Chiba, Tomoh Matsumiya, Hidemi Yoshida, Hiroshi Tanaka.   

Abstract

AIM: Mizoribine (MZR) is a selective inhibitor of the inosine monophosphate dehydrogenase - a key enzyme in the de novo pathway of guanine nucleotides - that was developed in Japan. Besides its immunosuppressive effects, MZR has recently been reported to suppress the progression of histologic chronicity via suppression of macrophage infiltration of the interstitium in selected patients with lupus nephritis.
METHODS: We examine the direct effect of MZR in human mesangial cells on the expression of functional molecules including monocyte chemoattractants in cultured human mesangial cells (MCs) treated with polyinosinic-polycytidylic acid (poly IC), a synthetic analogue of viral dsRNA, that makes 'pseudoviral' infection, and analyzed the expression of target molecules by reverse transcriptase-polymerase chain reaction and Western blotting. Thereafter, the effect of MZR on the expressions was examined.
RESULTS: Pretreatment of cells with MZR partially, but significantly, attenuates the expression of monocyte chemoattractant protein (MCP)-1 mRNA and protein, whereas the poly IC-induced expressions for the other functional molecules, such as CCL5, fractalkine and IL-8 were not influenced by MZR treatment. On the other hand, pretreatment of cells with tacrolimus did not suppress the expression of MCP-1 mRNA.
CONCLUSION: Mizoribine itself selectively attenuated the expression of MCP-1 both mRNA and protein levels in MCs treated with poly IC; that is, a possible model of 'pseudoviral' infection, which may be involved in the pathogenesis of lupus nephritis.
© 2013 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  human mesangial cells; lupus nephritis; mizoribine; monocyte chemoattractant protein-1; polyinosinic-polycytidylic acid

Mesh:

Substances:

Year:  2014        PMID: 24134561     DOI: 10.1111/nep.12171

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  3 in total

Review 1.  Mizoribine in the treatment of pediatric-onset glomerular disease.

Authors:  Hiroshi Tanaka; Kazushi Tsuruga; Taddatsu Imaizumi
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

Review 2.  Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.

Authors:  Hiroshi Tanaka; Kensuke Joh; Tadaatsu Imaizumi
Journal:  Clin Exp Nephrol       Date:  2017-03-03       Impact factor: 2.801

3.  Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1 in human mesangial cells.

Authors:  Tadaatsu Imaizumi; Tomomi Aizawa; Chihiro Segawa; Michiko Shimada; Kazushi Tsuruga; Shogo Kawaguchi; Tomoh Matsumiya; Hidemi Yoshida; Kensuke Joh; Hiroshi Tanaka
Journal:  Clin Exp Nephrol       Date:  2014-12-04       Impact factor: 2.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.